


## Beverly Glen Laboratories Inc. Unveils NuvoSome, A Revolutionary New Generation Delivery System for Cosmetics

NEWPORT BEACH, CA, UNITED STATES, May 3, 2023 /EINPresswire.com/ --Beverly Glen Laboratories Inc. Unveils NuvoSome, A Revolutionary New Generation Delivery System for <u>Cosmetics</u>

Beverly Glen Laboratories, Inc., a leading skincare research company, has announced the launch of NuvoSome, a groundbreaking drug delivery system for cosmetics. NuvoSomes are nanocapsules capable of encapsulating a large variety of cosmetic ingredients to enhance ingredient stability and ingredient performance. NuvoSomes uniquely



NuvoSome Magnified

feature a lipophilic group, or "tail", and a hydrophilic group, or "head", making these vesicles both lipid and water compatible.

## ٢

We are proud to be at the forefront of the groundbreaking technology and look forward to seeing how NuvoSome transforms the cosmetic industry."


Dr. Brian Keller, Chief Scientific Officer "We are excited to introduce NuvoSome to the cosmetic industry. The revolutionary drug delivery system represents a significant breakthrough in drug delivery technology, enabling the reliable and effective delivery of active ingredients in cosmetics formulations," said Dr. Brian Keller, Chief Scientific Officer for Beverly Glen Laboratories, Inc.

NuvoSome was designed and developed in Japan where it has undergone extensive pharmaceutical and clinical testing. As a Japanese-made product, NuvoSome conforms

to the highest quality GMP standards, ensuring that it is safe and effective for use in a variety of

cosmetic dosage forms and formulations. It has already received high praise for its effectiveness. NuvoSome conforms to the highest quality standards, ensuring that it is safe for use in cosmetic formulations. It's also been proven to penetrate the skin barrier effectively, making it an invaluable tool for cosmetics companies seeking to create products that deliver active ingredients effectively and reliably.

Moreover, NuvoSome has been awarded several patents for this revolutionary technology, including patents for its high antioxidant scavenging capacity and its ability to deliver added moisture to skin cells. These patents are a testament to the



Nuvosome with visible layers



groundbreaking technology behind NuvoSome and highlight its unique and unparalleled ability to enhance active ingredients. NuvoSome's patent portfolio, research data, manufacturing distinctive, and commercial applications ensure that it is unique and secures a place as a gamechanger in the cosmetic industry.

"We are proud to be at the forefront of the groundbreaking technology and look forward to seeing how NuvoSome transforms the cosmetic industry," added Dr. Brian Keller.

For more information about NuvoSome and Beverly Glen Laboratories, Inc., please visit our website <u>https://bit.ly/3LkY6qt</u> or contact us at (714) 848-5777 or info@bglen.us.

About Beverly Glen Laboratories, Inc.

Beverly Glen Laboratories, Inc. is a leading skincare research company dedicated to developing innovative solutions to improve skin health. With a commitment to excellence, Beverly Glen Laboratories, Inc., is at the forefront of scientific research and product development, ensuring that its products conform to the highest quality standards.

For more information or to arrange an interview, please contact: Steven Akimoto Accounts Manager (714) 848-5777 takimoto@bglen.us Tomomitsu Akimoto Beverly Glen Laboratories Inc +1 714-848-5777 info@bglen.us Visit us on social media: Facebook Instagram YouTube TikTok Other

This press release can be viewed online at: https://www.einpresswire.com/article/631599215

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2023 Newsmatics Inc. All Right Reserved.